Clinical trials · New York, NY
Lupus Erythematosus, Systemic clinical trials in New York
We’re tracking 28 recruiting lupus erythematosus, systemic studies with a site in or near New York — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT06617325RecruitingPhase 3
New drug for moderate to severe lupus
This study tests a new medicine called Dapirolizumab Pegol (given as an infusion) for people with moderate to severe lupus (SLE) that is not well controlled despite standard treatments. It aims to see if the drug can reduce lupus activity and prevent flares.
New York, New YorkAges 16 years+ - NCT00198068Recruiting
Study pregnancy outcomes in lupus and antiphospholipid syndrome
This study looks for factors that may predict how pregnancy turns out in people with lupus (SLE) and/or antiphospholipid syndrome (APS). It may help doctors better understand what to monitor in early pregnancy to support healthier outcomes.
New York, New YorkAges 18–45 - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
New York, New YorkAges 18 years+ - NCT04976322Enrolling by invitationPhase 3
Long-term lupus treatment safety study with dapirolizumab
This Phase 3 study tests whether dapirolizumab pegol is safe and tolerable for people with systemic lupus erythematosus (SLE) when taken long-term. You may be offered a chance to stay on this medicine if the study team thinks you could benefit.
New York, New YorkAges 16 years+ - NCT06897930RecruitingPhase 1/Phase 2
Testing a new drug for adults with lupus
This trial tests an investigational drug called AZD0120 in adults with lupus that hasn't improved with standard treatments. The goal is to see if it's safe and works well for people with lupus-related organ problems.
New York, New YorkAges 18–70 - NCT06875960RecruitingPhase 4
Continuing deucravacitinib for people with lupus
This study lets people who have already finished a previous trial of deucravacitinib continue taking the medicine. It is for adults with lupus, including skin-only forms of the disease, to see if long-term treatment remains safe and helpful.
New York, New YorkAges 18–75 - NCT05835310RecruitingPhase 3
IV anifrolumab for active lupus in children
This study tests whether an intravenous medicine called anifrolumab can safely improve active systemic lupus (SLE) in children. If you qualify, you may receive the study treatment and be closely monitored for safety and lupus symptoms.
New York, New YorkAges 5–17 - NCT05799378RecruitingPhase 3
Stopping hydroxychloroquine in older adults with stable lupus
This study looks at whether it is safe for people aged 55 and older with long-standing, stable lupus to stop taking hydroxychloroquine (a medicine that helps control lupus) without their disease flaring up. If you have been taking this medicine for at least 7 years and your lupus has been quiet for a while, you may be able to join.
New York, New YorkAges 55 years+ - NCT07038447Enrolling by invitationPhase 1
KITE-363 for refractory autoimmune diseases
This trial tests a new cell therapy called KITE-363 for people with certain autoimmune diseases (lupus, lupus nephritis, systemic sclerosis, or idiopathic inflammatory myopathy) that haven't improved with standard treatments. It aims to see if this therapy can help control the disease.
New York, New YorkAges 18 years+ - NCT07107659RecruitingEarly Phase 1
Testing ONT01 for active lupus
This trial tests a new drug called ONT01 for people with active lupus that is not affecting their kidneys. It is for those who have not had success with standard treatments.
New York, New YorkAges 18 years+ - NCT07085104RecruitingPhase 1
Study of ALLO-329 for lupus, myositis, or scleroderma
This trial tests a new one-time cell therapy (ALLO-329) made from donor cells to target and calm overactive immune cells in people with lupus, myositis, or scleroderma that hasn't improved with usual medications. It aims to see if this treatment is safe and can help reduce disease activity.
New York, New YorkAges 18–74 - NCT06570798RecruitingPhase 2
Testing Two Drugs for Lupus and Rheumatoid Arthritis
This trial tests two study drugs, inebilizumab and blinatumomab, for people with lupus (SLE) or rheumatoid arthritis (RA) that hasn't gotten better with standard treatments. It focuses on those with active disease, especially lupus-related kidney problems.
New York, New YorkAges 18–75 - NCT05559671RecruitingPhase 4
Shingles vaccine safety study for people with lupus
This Phase 4 study checks how safe a shingles vaccine (Shingrix, a non-live vaccine) is for adults with lupus. You might be invited if you have lupus and haven’t had certain shingles or chickenpox-related vaccines recently, and if your lupus symptoms and immune health meet the study rules.
New York, New YorkAges 18–90 - NCT06518668Enrolling by invitationPhase 1
NKX019 cell therapy for lupus
This study tests a new therapy called NKX019, which uses specially engineered natural killer cells to target a protein on lupus cells. It is for people with moderate to severe lupus that has not responded to standard treatments, especially those with active kidney inflammation.
New York, New YorkAges 18–65 - NCT07219563RecruitingPhase 1
Alnuctamab for hard-to-treat lupus (LATTE Study)
This trial tests a new drug called alnuctamab for people with lupus (SLE) that hasn't responded to multiple standard treatments. It aims to see if targeting certain immune cells can reduce lupus activity.
New York, New YorkAges 18–60 - NCT07221565Enrolling by invitationPhase 1/Phase 2
Immune mapping trial for autoimmune conditions
This trial is testing a new way to map the immune system using electromagnetic signals and forecast how your body's immune system will respond. It may help people with autoimmune conditions like lupus or rheumatoid arthritis find new treatment options.
New York, New YorkAges Any age - NCT06613360RecruitingPhase 1
Study of CLN-978 for people with systemic lupus erythematosus
This trial tests an experimental drug called CLN-978, given as a shot under the skin, that targets a protein on certain immune cells (B cells) to try to calm overactive immune activity in lupus. The goal is to see if it can reduce lupus symptoms for people whose disease has not been controlled by other treatments.
New York, New YorkAges 18–70 - NCT06308978RecruitingPhase 1
Study of FT819 for B-cell autoimmune diseases
This trial tests a new cell therapy, FT819, for people with certain autoimmune diseases like lupus, vasculitis, myositis, or scleroderma that haven't improved with at least two previous treatments. The goal is to see if it can help control the disease.
New York, New YorkAges 12–70 - NCT06121297RecruitingPhase 1/Phase 2
CABA-201 for active lupus
This trial tests a new treatment called CABA-201, which is a type of immune cell therapy (CAR T cells) for people with active lupus. The goal is to see if it's safe and can help control lupus symptoms.
New York, New YorkAges 18–65 - NCT05934149Recruiting
Lupus health registry that stores samples for future research
This study keeps a long-term record of people with lupus (systemic lupus erythematosus) and collects samples so researchers can study the disease better. You may be able to join if you meet lupus diagnosis criteria, are not pregnant, and can follow the study visits and consent process.
New York, New YorkAges 18–110 - NCT07053800RecruitingPhase 2
Obe-cel for severe lupus with kidney inflammation
This trial tests a new cell therapy called obe-cel in people ages 12 to 65 with severe systemic lupus erythematosus (SLE) that has not responded to other treatments and has caused active lupus nephritis (kidney disease). The goal is to see if obe-cel can reduce lupus activity and improve kidney health.
New York, New YorkAges 12–65 - NCT06411249RecruitingPhase 4
Belimumab for people with early lupus
This study tests whether a medicine called belimumab (Benlysta) works better for people diagnosed with lupus in the last 2 years. It aims to slow down the disease before it causes lasting organ damage.
Brooklyn, New YorkAges 18 years+ - NCT07175285Recruiting
Study for lupus patients not helped by steroids and 2 immunosuppressants
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
Brooklyn, New YorkAges 16 years+ - NCT05352919Enrolling by invitationPhase 3
Long-term study of litifilimab for lupus symptom control
This study follows people with systemic lupus erythematosus (SLE) who already took part in an earlier, 1-year placebo-controlled trial. It looks at the long-term safety of litifilimab and whether it helps improve lupus symptoms over time.
Brooklyn, New YorkAges 18 years+
Hear when a new Lupus Erythematosus, Systemic trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Lupus Erythematosus, Systemic trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting lupus erythematosus, systemic studies listed above.
- Columbia University Irving Medical Center · 8 studies
- NYU Langone Health · 5 studies
- Hospital for Special Surgery · 4 studies
- Icahn School of Medicine at Mount Sinai · 4 studies
- Montefiore Medical Center · 2 studies
- Northwell Health · 2 studies
- Research Site · 2 studies
- Sl00 50264 · 2 studies
What taking part in a lupus erythematosus, systemic study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting lupus erythematosus, systemic studies in New York.
Common questions
- Are there lupus erythematosus, systemic clinical trials near New York?
- Yes. We're currently tracking 28 recruiting lupus erythematosus, systemic studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lupus erythematosus, systemic study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lupus erythematosus, systemic trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lupus erythematosus, systemic studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.